School | Page 230 of 257 | SpiritIndia.com

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

ADHD :: Lisdexamfetamine dimesylate in ADHD phase 3 data presented

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking lisdexamfetamine dimesylate (NRP104/LDX) produced a “much improved” or “very much improved” rating on the Clinical Global Impressions ? Improvement score. These results were presented last weekend at a national meeting of child and adolescent psychiatrists.

Psychiatry :: Cognitive decline is often undetected

Many patients over the age of 65 who are hospitalized with an acute illness experience a subtle change in their cognitive ability that often goes undiagnosed, untreated and underreported. As a result, a patient’s ability to make decisions about his or her medical treatment may be negatively impacted.

ADHD :: Many adults with psychiatric disorders may also have undiagnosed ADHD

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that many adults with a depressive disorder, Bipolar Disorder (BPD), or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), according to a longitudinal retrospective medical claims analysis presented today at a major medical meeting of child and adolescent psychiatrists.

Breast Cancer :: Exercise helps breast cancer patients avoid anemia

Women undergoing radiation treatment for breast cancer benefit from moderate intensity, regular aerobic activity, according to a new study. A peer-reviewed journal of the American Cancer Society, the study found that exercise improved the oxygen capacity of patients and maintained levels of red blood cells during radiation treatment. In contrast, women who did not exercise experienced significant declines in their oxygen capacity. This is the first study to investigate the effect of exercise during treatment.

Health :: New approach to treat neglected tropical diseases

World Health Organization (WHO) and a group of more than 25 partner organizations unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people.

Diarrhea :: Point-of-Use Water Treatment Reduces Diarrhea in Refugee Camps

Point-of-use water treatment and improved water storage reduced the incidence of diarrhea by 90 percent when compared to improved water storage alone in camps for the internally displaced in Liberia, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. In camp settings during emergencies, diarrheal diseases have accounted for more than 40 percent of all deaths, and a majority of deaths of small children. The study evaluated Procter & Gamble’s (NYSE: PG) PUR(R) Purifier of Water and is the first to test the effectiveness of PUR under emergency conditions. It is published in the October 2006 edition of Tropical Medicine and International Health.

Psychiatry :: First Mani Bhaumik Award to UW Scientist for Insights into Brain’s Neuroplasticity

The Cousins Center for Psychoneuroimmunology at UCLA has named University of Wisconsin’s Richard Davidson as the first recipient of The Mani Bhaumik Award. The award was established earlier this year to support scientists in the international community who advance the understanding of the brain and the conscious mind in healing through visionary research, books and education. Bhaumik, co-inventor of the laser technology that made LASIK surgery possible, has funded the annual $10,000 award.

Contraception :: IUC is a preferred contraceptive of female

Intrauterine contraception (IUC) is very effective, with a failure rate of less than one percent (similar to that of sterilization), which is one reason why many female ob/gyns choose this method of birth control for themselves. In fact, research shows that female ob/gyns are nine times more likely to choose an IUC for themselves compared with women in general. Misinformation and misperceptions about the IUC may have contributed to its limited use among women in the U.S. to date.

Dyspepsia :: Zelnorm, tegaserod maleate for relief of multiple symptoms of dyspepsia – Novartis

The gastrointestinal medicine Zelnorm? (tegaserod maleate) has demonstrated potential benefits in helping patients with the multiple symptoms of a common digestive disorder called dysmotility-type dyspepsia[1], according to new Phase III data presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.